Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | GRK2 | P25098 | 3/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | GRK1 | Q15835 | 2/20 | 0.40 |
| ▸ | GRK5 | P34947 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3912721 | 0.76 | CYP11B1 (0.54) | CYP11B1CYP11B2IDO1HPGDSSMN1; SMN2 | |
| SCHEMBL12794259 | 0.76 | HSP90AA1 (0.55) | CYP11B1CYP11B2IDO1HPGDSSMN1; SMN2 | |
| SCHEMBL13101585 | 0.74 | ALDH1A1 (0.51) | CYP11B1CYP11B2IDO1SMN1; SMN2KDM4E | |
| SCHEMBL28017590 | 0.72 | CYP11B2 (0.51) | CYP11B1CYP11B2IDO1KDM4ELMNA | |
| SCHEMBL6496747 | 0.72 | CYP11B1 (0.63) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL6502454 | 0.72 | CYP11B1 (0.61) | CYP11B1CYP11B2IDO1HPGDSP2RX7 | |
| SCHEMBL12376644 | 0.72 | BRD4 (0.57) | CYP11B1CYP11B2IDO1SMN1; SMN2KDM4E | |
| SCHEMBL12411780 | 0.71 | BRD4 (0.65) | CYP11B1CYP11B2SMN1; SMN2KDM4E | |
| SCHEMBL3913086 | 0.71 | ABCC8 (0.49) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL12561621 | 0.70 | BRD4 (0.67) | CYP11B1CYP11B2SMN1; SMN2KDM4EP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | CYP11B1 194/4885CYP11B2 190/4885IDO1 2645/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | CYP11B1 306/4885CYP11B2 349/4885IDO1 935/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | CYP11B1 2/4885CYP11B2 3/4885IDO1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.